<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903954</url>
  </required_header>
  <id_info>
    <org_study_id>NP28302</org_study_id>
    <nct_id>NCT01903954</nct_id>
    <nct_alias>NCT01281423</nct_alias>
  </id_info>
  <brief_title>A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety
      of setrobuvir in patients with genotype 1 chronic hepatitis C. Treatment-na誰ve patients will
      be randomized to receive either setrobuvir (800 mg orally b.i.d loading dose followed by 200
      mg orally .b.i.d.) or placebo in combination with standard of care Pegasys (peginterferon
      alfa-2a) and Copegus (ribavirin). Treatment duration will be 28 weeks or 48 weeks depending
      on response. Treatment-experienced patients categorized as relapsers, partial responders and
      viral breakthrough patients to previous pegylated interferon and ribavirin therapy will be
      randomized to receive either setrobuvir or placebo in combination with Pegasys and Copegus
      for 48 weeks. Treatment-experienced patients categorized as null-responders to previous
      pegylated interferon and ribavirin therapy will be assigned to treatment with setrobuvir plus
      Pegasys and Copegus for 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving sustained virologic response (SVR24), defined as undetectable hepatitis C virus (HCV) RNA at 24 weeks after discontinuation of all study drugs</measure>
    <time_frame>24 weeks after discontinuation of all study drugs (treatment duration 28 or 48 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving undetectable HCV RNA (defined as HCV RNA &lt; 15 IU/mL) at each visit through Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment-na誰ve patients eligible to stop all treatment at Week 28</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>up to approximately 72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Setrobuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly</description>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_label>Setrobuvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Orally b.i.d.</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>1000 mg or 1200 mg orally daily</description>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_label>Setrobuvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>setrobuvir</intervention_name>
    <description>Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks</description>
    <arm_group_label>Setrobuvir</arm_group_label>
    <other_name>ANA598</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18 to 65 years of age inclusive

          -  Documented chronic hepatitis C

          -  Treatment-na誰ve (no prior exposure to Pegasys, Copegus, or experimental HCV therapy)
             or treatment-experienced with current standard of care (Pegasys and Copegus) but
             categorized as null-responder or patients with partial response, relapse or viral
             breakthrough during or following prior treatment

          -  Serum HCV RNA &gt;/= 50,000 IU/mL at screening

          -  HCV antibody positive at screening

          -  HCV genotype 1

          -  Body mass index (BMI) 18-38 kg/m2

          -  In good health other than chronic HCV infection in the judgment of the principal
             investigators

          -  Negative for hepatitis B and HIV infection

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  For treatment-na誰ve patients: any previous treatment for HCV infection

          -  For treatment-experienced patients: previous treatment with an experimental therapy
             for HCV infection

          -  Co-infection with HIV or hepatitis C virus (HBV)

          -  History or evidence of decompensated liver disease

          -  History or evidence of hepatocellular carcinoma

          -  History of alcohol abuse and/or other drug addiction &lt;/= 1 year prior to enrollment in
             the study

          -  Poorly controlled diabetes mellitus

          -  One or more additional known primary causes of liver disease other than hepatitis C

          -  History of acute or chronic pancreatitis

          -  Participation in an other clinical study of a new chemical entity within 30 days prior
             to study randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <disposition_first_submitted>July 7, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 11, 2016</disposition_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

